ProKyma
Liverpool
About ProKyma
ProKyma develops cell separation technology to improve molecular biology tests. ProKyma’s own focus lies in developing an improved blood test for Circulating Tumour Cells (CTC's) to improve detection of early metastasis of cancers and subsequent monitoring of the response to therapy. The company is a spinout from Dstl Porton Down, to exploit Dstl’s research into separation technologies. The company’s expertise lies in the use of high frequency ultrasound along with magnetism to manipulate, concentrate, and purify biological cells from complex samples – a technique that has diverse applications in the clinical, food, environmental, and pharmaceutical sectors.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Last round: Series Unknown (Jun 2017)
- Website: prokyma.com
Industries & Categories
Biotechnology, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/prokyma-2308390 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.